Vectura Share Discussion Threads

[cap160] 26/9/2016 15:20

Not another run in up and run it back down again day is it?

[fhmktg] 26/9/2016 13:33

Please share richtea.

[cap160] 26/9/2016 12:52

A good few healthy buys going through

[richtea1701] 26/9/2016 10:42

Nice move up just after 9am today. I have my theories :)

[adamb1978] 25/9/2016 22:05

When the company said in their AGM statement that they were raising their 2016 revenue expectations, does anyone know whether they gave any guidance on what the figure is?
Thanks

Adam

[taffy100] 23/9/2016 15:29

Consilium Strategic Communications wins Vectura account

[celeritas] 23/9/2016 10:56

I like to avg up but have such a small holding a bit lower would be nice to add.

[diesel] 23/9/2016 09:12

Have we reversed the downtrend, next few days are key, we could do with something positive, settlement with GSK or news from Novartis..

[celeritas] 22/9/2016 15:14

Ultibron is superior to seretide as reported. Now if Ultibron can build up to sales of Seretide bob will very much be your uncle or aunt if he decides on the change.



Seretide peaked at $8b, hopefully Ultibron and Seebri can eventually can pass those figures.

[alexchry] 22/9/2016 13:21

Carpadium - Welcome though the milestone payment would be, Exparel is still a sideshow. VEC's future depends upon the success of products and treatments aimed at inhaled airways diseases. There has been a lack of good news on this front recently and the COPD trial was a major disappointment which is why I am eager to hear some good news regarding the marketing of Utibron and Seebri in the USA.

[best1467] 22/9/2016 12:29

Pacira dropped 8% on the news yesterday ,not sure why

[carpadium] 22/9/2016 12:27

VEC is eligible to receive US$32 milestone payment when worldwide annual net sales reach US$500m, they're currently not far short of US$300m already and that's US sales only. So any addressable new market is highly welcome, Exparel hardly a sideshow.

[alexchry] 22/9/2016 12:08

Exparel a sideshow, what we need is an announcement from Novartis re Utibron and Seebri, due by the end of this month.

[celeritas] 22/9/2016 12:00

Still weighing when to buy some of these.
The 5 year chart looks great, longer term it should follow the same path.

[fhmktg] 22/9/2016 11:14

Patents expire September 2018.

[fhmktg] 22/9/2016 11:06

When does the licence for Exparel terminateIs it as early as 2017?

[soundbuy] 22/9/2016 11:03

Excellent...every little helps.

[fhmktg] 22/9/2016 10:51

RNS quickly please!

[nw99] 21/9/2016 15:38

200p target

[pooroldboy55] 21/9/2016 13:42

Just like yesterday up till mid day then work it back down only today doit quicker

[nw99] 21/9/2016 13:09

Sellers overdone chart support